Apollomics Inc. Doses First Patient in Phase III Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

By
Justin.choi
-
0
37
Apollomics, Inc. announced that the first patient has been successfully dosed in a Phase III clinical trial of APL-106 for the treatment of adults with relapsed or refractory acute myeloid leukemia in China.
[Apollomics, Inc.]

Sorry, but the selected Zotpress account can't be found.

Press Release